Navigation Links
scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates

BOSTON, April 8, 2013 /PRNewswire/ -- scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure.  The terms of the agreement were not disclosed.

The drug-device combination uses the Sensile SenseCore technology in a wearable minipump that delivers the pharmaceutical drug product under the skin using a very small needle.  The pharmaceutical product is a proprietary reformulation of a proven diuretic that already forms the cornerstone of heart failure therapy.  Diuretics remove excess fluid retained by the body by increasing urinary output.  The diuretic that will be used with the minipump is a novel formulation of the diuretic furosemide, which has been in clinical use for nearly 50 years.  Furosemide is currently used in tablet form or in solution for intravenous administration.  Furosemide required a proprietary reformulation to render it suitable for subcutaneous administration.

Under the product development agreement, Sensile and scPharmaceuticals will collaborate to develop and manufacture minipump devices for use by scPharmaceuticals for its furosemide drug product for subcutaneous administration.  scPharmaceuticals expects to submit its New Drug Application for the furosemide drug device combination no later than Q1 of 2015.

"Hospitalization for heart failure is expected to be one of the most important reasons for the projected increase in health care costs over the next decade as our population ages and the epidemic of obesity and diabetes continues unabated," said Dr. Bertram Pitt , Professor of Medicine Emeritus at the University of Michigan School of Medicine and one of the co-founders of scPharmaceuticals.  "This innovative product is expected to provide rapid and more effective diuretic therapy that can be used at home under physician guidance when the patient experiences symptoms of decompensation.  We expect that this innovative approach will in many cases avert the need for emergency or in-hospital care, and for those patients who still require hospitalization, their hospital stay will be shortened and their outcomes improved."

"The reformulated furosemide product represents an excellent example of how an important new medical paradigm can be created by delivering a proven drug for the first time by subcutaneous delivery," said Derek Brandt , Chief Executive Officer of Sensile Medical AG, Hagendorf, Switzerland.  "It illustrates the importance of drug delivery technology to create novel, more cost-effective therapies aimed to save the healthcare system money and improve patient outcomes."

"The Affordable Care Act has created an urgent need for novel therapies that offer benefits comparable to those achieved by intravenously administered drugs in the hospital, but which can be administered anytime anywhere by the patient," said Pieter Muntendam , MD, President and Chief Executive Officer of scPharmaceuticals.  "Although numerous technologies have been pursued for small and convenient minipumps, the SenseCore minipump technology stands out because of its precision and the unique and cost-effective two component design of a versatile reusable battery-operated engine and the low cost disposable component that includes the drug delivery component."

About scPharmaceuticals

scPharmaceuticals LLC was formed in 2013 to continue the groundbreaking work of SpringLeaf Therapeutics, a Boston area company that was founded in 2007.  scPharmaceuticals is pursuing the largely untapped opportunity of treating patients for serious and life-threatening conditions with convenient anytime anywhere subcutaneous drug administration.  scPharmaceuticals uses a two component minipump developed by Sensile Medical AG.  scPharmaceuticals is developing a portfolio of innovative products by reformulating existing drugs to make them suitable for subcutaneous administration using the minipump delivery system. For further information see

About Sensile Medical

Sensile Medical AG is a leading company in the area of micro-pumps and patch-pumps.  These pumps are increasingly being used to enable Large-Volume Sub-Cutaneous delivery of modern pharmaceutical and biotech products for self-administration by patients.  Sensile Medical solutions utilize electronically controlled rotary piston pump technology for highly accurate dosing regimens, enabling a broad range of drug delivery options.  Founded in 2004, Sensile Medical is located in Hagendorf, Switzerland.  For further information see

SOURCE scPharmaceuticals LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hanger, Inc. Announces First Quarter 2013 Earnings Release And Conference Call
2. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
3. Uroplasty Announces CEO Resignation
4. Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
5. MEI Pharma Announces $15.2 Million Registered Offering Of Common Stock
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2013 Results
9. MedFocusCapital Partners Announces See.Hear.Live.Better! Alliance
10. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
11. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
Breaking Medicine News(10 mins):